These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 23940080)

  • 1. Effect of taxane-based neoadjuvant chemotherapy on fibroglandular tissue volume and percent breast density in the contralateral normal breast evaluated by 3T MR.
    Chen JH; Pan WF; Kao J; Lu J; Chen LK; Kuo CC; Chang CK; Chen WP; McLaren CE; Bahri S; Mehta RS; Su MY
    NMR Biomed; 2013 Dec; 26(12):1705-13. PubMed ID: 23940080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decrease in breast density in the contralateral normal breast of patients receiving neoadjuvant chemotherapy: MR imaging evaluation.
    Chen JH; Nie K; Bahri S; Hsu CC; Hsu FT; Shih HN; Lin M; Nalcioglu O; Su MY
    Radiology; 2010 Apr; 255(1):44-52. PubMed ID: 20308443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of neoadjuvant chemotherapy on breast tissue composition: a longitudinal mammographic study with automated volumetric measurement.
    Jang HJ; Kim HJ; Chae YS; Lee SJ; Kim SH; Lee H; Kim WH
    Eur Radiol; 2020 Sep; 30(9):4785-4794. PubMed ID: 32314056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Background parenchymal enhancement in the contralateral normal breast of patients undergoing neoadjuvant chemotherapy measured by DCE-MRI.
    Chen JH; Yu H; Lin M; Mehta RS; Su MY
    Magn Reson Imaging; 2013 Nov; 31(9):1465-71. PubMed ID: 23992630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of breast density following tamoxifen treatment evaluated by 3-D MRI: preliminary study.
    Chen JH; Chang YC; Chang D; Wang YT; Nie K; Chang RF; Nalcioglu O; Huang CS; Su MY
    Magn Reson Imaging; 2011 Jan; 29(1):91-8. PubMed ID: 20832226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consistency of breast density measured from the same women in four different MR scanners.
    Chen JH; Chan S; Liu YJ; Yeh DC; Chang CK; Chen LK; Pan WF; Kuo CC; Lin M; Chang DH; Fwu PT; Su MY
    Med Phys; 2012 Aug; 39(8):4886-95. PubMed ID: 22894415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between tumour size and response to neoadjuvant chemotherapy among breast cancer patients in a tertiary center in Nigeria.
    Samuel O; Olayide A; Ganiyu R; Olufemi H; Halimat A
    Malawi Med J; 2018 Mar; 30(1):13-16. PubMed ID: 29868153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optical imaging correlates with magnetic resonance imaging breast density and reveals composition changes during neoadjuvant chemotherapy.
    O'Sullivan TD; Leproux A; Chen JH; Bahri S; Matlock A; Roblyer D; McLaren CE; Chen WP; Cerussi AE; Su MY; Tromberg BJ
    Breast Cancer Res; 2013 Feb; 15(1):R14. PubMed ID: 23433249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological outcomes of HER2-positive non-metastatic breast cancer patients treated with neoadjuvant dual anti-HER2 therapy and taxane: An Australian experience.
    Choi JDW; Hughes TMD; Marx G; Rutovitz J; Hasovits C; Ngui NK
    Asia Pac J Clin Oncol; 2020 Jun; 16(3):103-107. PubMed ID: 31218842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased aldehyde dehydrogenase 1 (ALDH1) levels are associated with chemo-responsiveness in breast cancer patients treated with taxane-adriamycin-cyclophosphamide regimen.
    Hapidah H; Djabir YY; Prihantono P
    Breast Dis; 2021; 40(S1):S33-S37. PubMed ID: 34057116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opportunistic Breast Density Assessment in Women Receiving Low-dose Chest Computed Tomography Screening.
    Chen JH; Chan S; Lu NH; Li Y; Tsai YC; Huang PY; Chang CJ; Su MY
    Acad Radiol; 2016 Sep; 23(9):1154-61. PubMed ID: 27283069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer.
    Tan MH; De S; Bebek G; Orloff MS; Wesolowski R; Downs-Kelly E; Budd GT; Stark GR; Eng C
    Breast Cancer Res Treat; 2012 Feb; 131(3):849-58. PubMed ID: 21479552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
    Goble S; Bear HD
    Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of endogenous hormonal levels, fibroglandular tissue volume and percent density measured using 3D MRI during one menstrual cycle.
    Chen JH; Chen WP; Chan S; Yeh DC; Su MY; McLaren CE
    Ann Oncol; 2013 Sep; 24(9):2329-35. PubMed ID: 23661294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
    Lee HJ; Park IA; Song IH; Kim SB; Jung KH; Ahn JH; Ahn SH; Kim HH; Gong G
    PLoS One; 2015; 10(9):e0137885. PubMed ID: 26394326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of obesity on pathological complete response and survival in breast cancer patients receiving uncapped doses of neoadjuvant anthracycline-taxane-based chemotherapy.
    Farr A; Stolz M; Baumann L; Bago-Horvath Z; Oppolzer E; Pfeiler G; Seifert M; Singer CF
    Breast; 2017 Jun; 33():153-158. PubMed ID: 28395233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.
    Charehbili A; Wasser MN; Smit VT; Putter H; van Leeuwen-Stok AE; Meershoek-Klein Kranenbarg WM; Liefers GJ; van de Velde CJ; Nortier JW; Kroep JR
    Eur J Surg Oncol; 2014 Oct; 40(10):1216-21. PubMed ID: 25150151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy - A retrospective pooled analysis of individual patients data of four German neoadjuvant trials.
    Reinisch M; Huober J; von Minckwitz G; Blohmer JU; Denkert C; Hanusch C; Jackisch C; Kümmel S; Schneeweiss A; Rhiem K; Lederer B; Untch M; Nekljudova V V; Loibl S
    Breast; 2017 Apr; 32():73-78. PubMed ID: 28063331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes.
    Lo WC; Li W; Jones EF; Newitt DC; Kornak J; Wilmes LJ; Esserman LJ; Hylton NM
    PLoS One; 2016; 11(2):e0142047. PubMed ID: 26886725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of adding taxane to anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer.
    Rašić A; Sofić A; Bešlija S; Rašić I; Hasanbegović B
    Med Glas (Zenica); 2019 Feb; 16(1):77-82. PubMed ID: 30256061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.